Greiner Bio-One is specialised in the development, production and distribution of plastic laboratory products. The company is a technology partner for universities, hospitals, research institutes and the diagnostic, pharmaceutical and biotechnology industries as well.
Greiner Bio-One is specialised in the development, production and distribution of plastic laboratory products. The company is a technology partner for universities, hospitals, research institutes and the diagnostic, pharmaceutical and biotechnology industries as well.
Greiner Bio-One GmbH is a division of Greiner Bio-One International AG, based in Kremsmuenster (Austria). Today Greiner Bio-One International AG generates a turnover of 364 million euros. It has over 1,700 employees and operates globally with 24 subsidiaries and numerous distributors in more than 100 countries.
Greiner Bio-One is a leading supplier of special products for cell cultures and microplates for high-throughput screening and a developer of innovative biochips and sample collection systems. The company performs contract work from the pharmaceutical industry, the diagnostic and medical sectors. Greiner Bio-One uses injection moulding to produce a whole range of customised plastic platforms for the life sciences sector and offers the complete product development and production process from the idea through to the finished product. The company produces small and large series, undertakes customer-specific branding and can call on production facilities in Europe, the U.S. and Asia.
Visit us at CPhI/ICSE/P-MEC Hall and stand number: Hall 4.1, Booth No. 41H09
Greiner Bio-One GmbH
Bad Haller Strasse 32, 4550 Kremsmuenster, Austria
Telephone: +43 7583 67910 Fax: +43 7583 6318
E-mail: office@at.gbo.com
Website: www.gbo.com
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
PacBio Chosen as Tech Partner for Global Alzheimer’s Disease Research Project
April 23rd 2025The project, the North African Dementia Registry, will unite multiple entities for the purpose of developing a comprehensive dataset to advance the research community’s understanding of Alzheimer’s disease and other dementias in diverse populations.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.